AAO 2021

Innovent Presented Results of IBI302 in P-Ib Clinical Trial for the Treatment of Neovascular Age-Related Macular Degeneration at AAO 2021

Shots: The P-Ib clinical trial evaluates the safety & tolerability of IBI302 multi-intravitreal injection in 18 patients with nAMD The results showed an improvement in visual acuity & reduction in retinal edema were observed @4wks. after three loading treatments. The therapy was safe and well-tolerated with no report of dose-limiting toxicity, & no treatment-related serious …

Innovent Presented Results of IBI302 in P-Ib Clinical Trial for the Treatment of Neovascular Age-Related Macular Degeneration at AAO 2021 Read More »

Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 2021

Shots: The ongoing P-II AAVIATE & ALTITUDE trial evaluates RGX-314 using suprachoroidal delivery in patients with wet AMD & DR without CI-DME, respectively In the P-II AAVIATE trial, the therapy showed stable visual acuity & retinal thickness, >70% reduction in anti-VEGF treatment burden @6mos., 40% of patients were anti-VEGF inj.-free & was well tolerated in …

Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 2021 Read More »